Integral Diagnostics Ltd reports: Underlying NPAT up 22.7%

Integral Diagnostics Ltd (ASX:IDX) reported a good set of numbers today.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Integral Diagnostics Ltd (ASX: IDX) reported its half-year result to 31 December 2017 today.

Integral Diagnostics is one of the larger radiology businesses on the ASX. Here are some of the highlights from its report compared to the prior corresponding period to 31 December 2016:

  • Operating revenue up 5.8% to $92.8 million
  • Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) up 12.4% to $19 million
  • Underlying earnings before interest and tax (EBIT) up 17.6% to $14 million
  • Underlying net profit after tax (NPAT) up 22.7% to $9.2 million
  • Free cash flow increased by 70.2% to $17.7 million.
  • Cash and cash equivalents increased by $4 million.

Underlying profit is the best measure of performance because the statutory performance includes one-off acquisition costs.

Management believe that the long-term drivers remain for the business. A number of Medicare and government changes means that the business' future is rosier than before.

The ageing population of Australia will also be a very positive tailwind for the business over the coming years.

The business expects that normalised FY18 NPAT for the whole year will come in at around 20%, this prediction excludes the takeover costs.

Management expect to deliver revenue growth stronger than previously expected, better cost efficiency initiatives, a lower effective tax rate and lower capital spending due to economies of scale.

The board also gave an update about the takeover offer from Capitol Health Ltd (ASX: CAJ). The board re-iterated that shareholders should do nothing until they have read Integral Diagnostics' target's statement, which will be provided no more than 15 days after Capital Health has dispatched its bidder's statement. The target's statement will contain the Board's recommendation.

Capitol may bid a higher amount for Integral, but I wouldn't buy shares just for that purpose.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »